Serratia bacteremia in a Large University Hospital: Trends in antibiotic resistance during 10 years and implications for antibiotic use

Infection Control and Hospital Epidemiology

Volumn 23, Issue 12, 2002, Pages 740-747

  Choi, Sang Ho ^a   Kim, Yang Soo ^a   Chung, Jin Won ^a   Kim, Tae Hyong ^a   Choo, Eun Ju ^a   Kim, Mi Na ^a   Kim, Baek Nam ^b   Kim, Nam Joong ^a   Woo, Jun Hee ^a,c   Ryu, Jiso ^a  

^a University of Ulsan College of Medicine   (South Korea)

^b Dongsan Medical Center   (South Korea)

^c Asan Medical Center   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; PENICILLIN DERIVATIVE; PIPERACILLIN; TOBRAMYCIN;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTEREMIA; BACTERIUM ISOLATE; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; RISK FACTOR; SERRATIA MARCESCENS; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BACTEREMIA; CEPHALOSPORINS; CHILD; CHILD, PRESCHOOL; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; INFANT; INFANT, NEWBORN; KOREA; LENGTH OF STAY; MALE; MIDDLE AGED; MORBIDITY; RECURRENCE; RETROSPECTIVE STUDIES; RISK FACTORS; SERRATIA INFECTIONS; SURVIVAL RATE;

EID: 0036912298     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502004     Document Type: Article

References (52)

1. Gatell JM, Trilla A, Latorre X, et al. Nosocomial bacteremia in a large Spanish teaching hospital: Analysis of factors influencing prognosis. Rev Infect Dis 1988;10:203-210.
2. Pfaller MA, Jones RN, Marshall SA, et al. Inducible amp C beta-lactamase producing gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). Diagn Microbiol Infect Dis 1997;28:211-219.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: A three-year analysis. Clin Infect Dis 1999;29:239-244.
4. Richards NM, Levitsky S. Outbreaks of Serratia marcescens infections in a cardiothoracic surgical intensive care unit. Ann Thorac Surg 1975;19:503-513.
5. Geiseler PJ, Harris B, Andersen BR. Nosocomial outbreak of nitrate-negative Serratia marcescens infections. J Clin Microbiol 1982;15:728-730.
6. Duggan TG, Leng RA, Hancock BM, Cursons RT. Serratia marcescens in a newborn unit: Microbiological features. Pathology 1984;16:189-191.
7. Fry DE, Fry RV, Shlaes DM. Serratial bacteremia in the surgical patient. Am Surg 1987;53:438-441.
8. Villarino ME, Jarvis WR, O'Hara C, Bresnahan J, Clark N. Epidemic of Serratia marcescens bacteremia in a cardiac intensive care unit. J Clin Microbiol 1989;27:2433-2436.
9. Sokalski SJ, Jewell MA, Asmus-Shillington AC, Mulcahy J, Segreti J. An outbreak of Serratia marcescens in 14 adult cardiac surgical patients associated with 12-lead electrocardiogram bulbs. Arch Intern Med 1992;152:841-844.
10. van Ogtrop ML, van Zoeren-Grobben D, Verbakel-Salomons EM, van Boven CP. Serratia marcescens infections in neonatal departments: Description of an outbreak and review of the literature. J Hosp Infect 1997;36:95-103.
11. Harnett SJ, Allen KD, Macmillan RR. Critical care unit outbreak of Serratia liquefaciens from contaminated pressure monitoring equipment. J Hosp Infect 2001;47:301-307.
12. Grohskopf LA, Roth VR, Feikin DR, et al. Serratia liquefaciens bloodstream infections from contamination of epoetin alfa at a hemodialysis center. N Engl J Med 2001;344:1491-1497.
13. Yu VL. Serratia marcescens: Historical perspective and clinical review. N Engl J Med 1979;300:887-893.
14. Eisenstein BI, Zaleznik DF. Enterobacteriaceae. In: Mandell GL, Douglas RG, Bennett JE, Dolin R, eds. Principles and Practice of Infectious Diseases, 5th Ed. Philadelphia: Churchill Livingstone; 2000:2297-2310.
15. Livermore DM. Clinical significance of β-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987;6:439-445.
16. Sanders CC, Sanders WE Jr. β-lactam resistance in gram-negative bacteria: Global trends and clinical impact. Clin Infect Dis 1992;15:824-839.
17. Bennett PM, Chopra I. Molecular basis of β-lactamase induction in bacteria. Antimicrob Agents Chemother 1993;37:153-158.
18. Dworzack DL, Pugsley MP, Sanders CC, Horowitz EA. Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins. Eur J Clin Microbiol 1987;6:456-459.
19. Dodson WH. Serratia marcescens septicemia. Arch Intern Med 1968;121:145-150.
20. Wilfert JN, Barrett FF, Kass EH. Bacteremia due to Serratia marcescens. N Engl J Med 1968;279:286-289.
21. Henjyoji EY, Whitson TC, Ohashi DK, Allen BD. Bacteremia due to Serratia marcescens. J Trauma 1971;11:417-421.
22. Crowder JG, Gilkey GH, White AC. Serratia marcescens bacteremia: Clinical observations and studies of precipitin reactions. Arch Intern Med 1971;128:247-253.
23. Bouza E, Garcia de la Torre M, Erice A, Cercenado E, Loza E, Rodriguez-Creixems M. Serratia bacteremia. Diagn Microbiol Infect Dis 1987;7:237-247.
24. Sánchez Ruano JJ, Garcia Díaz JD, Alonso Navas E Serratia marcescens bacteremia: A report of 83 cases [in Spanish]. Medica Clinica 1988;90:479-483.
25. Saito H, Elting L, Bodey GP, Berkey P. Serratia bacteremia: Review of 118 cases. Rev Infect Dis 1989;11:912-920.
26. Watanakunakorn C. Serratia bacteremia: A review of 44 episodes. Scand J Infect Dis 1989;21:477-483.
27. Wong WW, Wang LS, Cheng DL, et al. Serratia marcescens bacteremia. J Formos Med Assoc 1991;90:88-93.
28. Haddy RI, Mann BL, Nadkarni DD, et al. Nosocomial infection in the community hospital: Severe infection due to Serratia species. J Fam Pract 1996;42:273-277.
29. Yu WL, Lin CW, Wang DY. Serratia marcescens bacteremia: Clinical features and antimicrobial susceptibilities of the isolates. J Microbiol Immunol Infect 1998;31:171-179.
30. McCabe WR, Jackson GG. Gram-negative bacteremia: II. Clinical, laboratory, and therapeutic observations. Arch Intern Med 1962;110:856-864.
31. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: Clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991;115:585-590.
32. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing: Ninth Informational Supplement M100-S9. Wayne, PA: National Committee for Clinical Laboratory Standards; 1999.
33. Jones RN. Important and emerging β-lactamase-mediated resistances in hospital-based pathogens: The Amp C enzymes. Diagn Microbiol Infect Dis 1998;31:461-466.
34. D'Agata E, Venkataraman L, DeGirolami P, Weigel L, Samore M, Tenover F. The molecular and clinical epidemiology of Enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect 1998;36:279-285.
35. De Champs C, Rouby D, Guelon D, et al. A case-control study of an outbreak of infections caused by Klebsiella pneumoniae strains producing CTX-1 (TEM-3) beta-lactamase. J Hosp Infect 1991;18:5-13.
36. Jacoby GA. Extended-spectrum beta-lactamases and other enzymes providing resistance to oxyimino-beta-lactams. Infect Dis Clin North Am 1997;11:875-887.
37. Kaye KS, Fraimow HS, Abrutyn E. Pathogens resistant to antimicrobial agents: Epidemiology, molecular mechanisms, and clinical management. Infect Dis Clin North Am 2000;14:293-319.
38. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993;119:353-358.
39. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998;42:53-58.
40. Schiappa DA, Hayden MK, Matushek MG, et al. Ceftazidime-resistant Klebsiella pneumoniae and Escherichia coli bloodstream infection: A case-control and molecular epidemiologic investigation. J Infect Dis 1996;174:529-536.
41. Wiener J, Quinn JP, Bradford PA, et al. Multiple antibiotic-resistant Klebsiella and Escherichia coli in nursing homes. JAMA 1999;281:517-523.
42. Livermore DM. Beta-lactamases in laboratory and clinical resistance. Clin Microbiol Rev 1995;8:557-584.
43. Pitout JD, Sanders CC, Sanders WE Jr. Antimicrobial resistance with focus on β-lactam resistance in gram-negative bacilli. Am J Med 1997;103:51-59.
44. Jacobson KL, Cohen SH, Inciardi JF, et al. The relationship between antecedent antibiotic use and resistance to extended-spectrum cephalosporins in group I β-lactamase-producing organisms. Clin Infect Dis 1995;21:1107-1113.
45. Sahm DF, Storch G. Amp C β-lactamases. Pediatr Infect Dis J 1998;17:421-422.
46. Sanders WE Jr, Sanders CC. Inducible β-lactamases: Clinical and epidemiologic implications for use of newer cephalosporins. Rev Infect Dis 1988;10:830-838.
47. Livermore DM. Carbapenemases. J Antimicrob Chemother 1992;29:609-613.
48. Naas T, Vandel L, Sougakoff W, Livermore DM, Nordmann P. Cloning and sequence analysis of the gene for a carbapenem-hydrolyzing class A βlactamase, Sme-1, from Serratia marcescens S6. Antimicrob Agents Chemother 1994;38:1262-1270.
49. Palomar J, Puig M, Montilla R, Loren JG, Vinas M. Lipopolysaccharide recovery restores susceptibility levels towards β-lactamase in Serratia marcescens. Microbios 1995;82:21-26.
50. Cunha BA. Antibiotic resistance. Med Clin North Am 2000;84:1407-1429.
51. Friedrich LV, White RL, Bosso JA. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infect Dis 1999;28:1017-1024.
52. Kaye KS, Cosgrove S, Harris A, Eliopoulos GM, Carmeli Y. Risk factors for emergence of resistance to broad-spectrum cephalosporins among Enterobacter spp. Antimicrob Agents Chemother 2001;45:2628-2630.